Peptide Comparison
Dulaglutide vs Orforglipron
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Dulaglutide and Orforglipron share the glp-1 class and carry roughly equivalent evidence (FDA-Approved / FDA-Approved). On the catalogued data layer Dulaglutide has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Dulaglutide's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Dulaglutide | Orforglipron | |
|---|---|---|
| Class | GLP-1 receptor agonist | Oral non-peptide GLP-1 agonist |
| Drug class | Metabolic & Weight | Metabolic & Weight |
| Mechanism | GLP-1 receptor agonist fused to human IgG4 Fc | Small-molecule non-peptide GLP-1 receptor agonist; orally bioavailable; binds the receptor upper helical bundle rather than the orthosteric peptide site; G-protein-biased partial agonist with minimal beta-arrestin recruitment [14] |
| Route | SC injection | Oral |
| Half-life | ~5 days | ~29-49 hrs |
| Dosage (research) | 0.75 mg SC weekly (Trulicity label starting dose, escalate stepwise to 1.5, 3.0, then label max 4.5 mg weekly for additional glycemic control per AWARD trials) | 0.8 mg orally once daily (FOUNDAYO label starting dose, escalate at intervals of at least 30 days through 2.5, 5.5, 9 and 14.5 mg to label max 17.2 mg once daily) [15] |
| Evidence tier | FDA-Approved | FDA-Approved |
| Research depth | 311 indexed | 197 indexed |
| Availability | Prescription | Prescription |
| Reported risks | Nausea; diarrhea; pancreatitis risk; thyroid C-cell tumor warning | GI effects; hepatic enzyme elevations |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Dulaglutide or Orforglipron?
Dulaglutide and Orforglipron share the glp-1 class and carry roughly equivalent evidence (FDA-Approved / FDA-Approved). On the catalogued data layer Dulaglutide has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Dulaglutide's evidence base is currently denser.
What is the difference between Dulaglutide and Orforglipron?
Dulaglutide is classed as GLP-1 receptor agonist; Orforglipron is classed as Oral non-peptide GLP-1 agonist. Reported mechanism: Dulaglutide, GLP-1 receptor agonist fused to human IgG4 Fc; Orforglipron, Small-molecule non-peptide GLP-1 receptor agonist; orally bioavailable; binds the receptor upper helical bundle rather than the orthosteric peptide site; G-protein-biased partial agonist with minimal beta-arrestin recruitment. Reported half-life: Dulaglutide, ~5 days; Orforglipron, ~29-49 hrs. Routes in published studies: Dulaglutide, SC injection; Orforglipron, Oral.
Which has stronger evidence, Dulaglutide or Orforglipron?
Dulaglutide and Orforglipron sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Dulaglutide is graded FDA-Approved, with 41 cited sources on its reference page and 311 indexed studies. Orforglipron is graded FDA-Approved, with 38 cited sources on its reference page and 197 indexed studies.
Which is more accessible, Dulaglutide or Orforglipron?
Both Dulaglutide and Orforglipron are FDA-approved drugs. Catalog status: Dulaglutide, Prescription; Orforglipron, Prescription.
Are Dulaglutide and Orforglipron ever combined?
Dulaglutide and Orforglipron appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…